Contineum Therapeutics (NASDAQ: CTNM) announced that its Phase 2 MOONLIGHT-1 trial evaluating JNJ-5120/PIPE-307 for the treatment of major depressive disorder ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE